Department of Hematology, University Medical Centre Ljubljana, Zaloška 7, 1000, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000, Ljubljana, Slovenia.
Ann Hematol. 2020 Mar;99(3):519-525. doi: 10.1007/s00277-020-03923-9. Epub 2020 Jan 23.
One hundred and eight consecutive acute myeloid leukemia (AML) patients aged 60 or less treated with two different induction regimens were retrospectively analyzed. Induction regimen for the first 50 consecutive patients was DA3+7, and the following 58 patients received cladribine 5 mg/m on days 1 through 5 in addition to DA3+7 (DAC). There were no significant differences in the median age and the proportion of patients with unfavorable characteristics between the two groups. Remission after induction chemotherapy was achieved in 30/50 (60%) patients in DA3+7 and in 46/58 (79%) in DAC group (p = 0.028). The median survival in the DA3+7 group was 18 months, while in the DAC group it was not reached (p = 0.034). We confirmed results from other research groups by demonstrating improved remission induction rate and overall survival of AML patients aged 60 years or less treated with DAC induction compared with standard DA3+7 induction chemotherapy.
回顾性分析了 108 例年龄在 60 岁以下的连续急性髓系白血病（AML）患者，他们接受了两种不同的诱导方案治疗。前 50 例连续患者的诱导方案为 DA3+7，随后的 58 例患者在 DA3+7 的基础上接受了克拉屈滨 5mg/m2，每天 1 次，共 5 天（DAC）。两组患者的中位年龄和不良特征的比例无显著差异。在 DA3+7 组中，30/50（60%）例患者诱导化疗后缓解，而 DAC 组中缓解 46/58（79%）例（p=0.028）。DA3+7 组的中位生存期为 18 个月，而 DAC 组未达到（p=0.034）。我们通过证明 DAC 诱导与标准 DA3+7 诱导化疗相比，可提高 60 岁以下 AML 患者的缓解诱导率和总生存率，证实了其他研究小组的结果。
